Study finds that treatment of depression can increase work productivity

 

Toronto, Canada (January 11, 2012) – A new study from the Centre for Addiction and Mental Health (CAMH) has found that employees with depression who receive treatment while still working are significantly more likely to be highly productive than those who do not. This is the first study of its kind to look into a possible correlation between treatment and productivity.

 

The study is particularly significant at a time when the Canadian economy continues to face uncertainty. Mental illness costs the Canadian economy an estimated $51 billion annually, with a third of that attributed to productivity losses.

 

Published in the current issue of the Canadian Journal of Psychiatry, the study examined data from a large-scale community survey of employed and recently employed people in Alberta.

 

People who experienced a depressive episode were significantly less likely to be highly productive, the study showed. "We expected this, as past research has found that depression has adverse effects on comprehension, social participation, and day-to-day-functioning," said Dr. Carolyn Dewa, head of CAMH’s Centre for Research on Employment and Workplace Health and lead author.

 

"What’s exciting is we found that treatment for depression improves work productivity. People who had experienced a moderate depressive episode and received treatment were 2.5 times more likely to be highly productive compared with those who had no treatment," she said. "Likewise, people who experienced severe depression were seven times more likely to be high-performing than those who had no treatment."

 

Of the 3,000 workers in the in the sample, 8.5 per cent experienced a depressive episode, representing 255 workers.

 

Though the results showed the effectiveness of treatment on work and performance, the data also showed a troubling trend. "We found that among all study participants who had been diagnosed with a severe depressive episode, 57 per cent did not receive treatment; 40 per cent of those who experienced a moderate depressive episode did not receive treatment," said Dr. Dewa. "When we look at the success of workers in the sample who received treatment while still in the workplace, it really speaks to the importance of prevention and the need for employers to facilitate treatment and support. If people are able to receive treatment early, disability leave, which costs companies $18,000 per leave, may be avoided."

 

"Stigma and discrimination have often affected people’s willingness to access to services, as has the lack of knowledge around supports available in the workplace," added Dr. Dewa. "It is crucial that employers offer mental health interventions to their employees and support them in engaging in treatment, as well as continuing to support them as they transition back into the workplace."

 

The data for this analysis was collected by the Institute for Health Economics, Alberta.

 

 

The Centre for Addiction and Mental Health (CAMH) is Canada’s largest mental health and addiction teaching hospital, as well as one of the world’s leading research centres in the area of addiction and mental health. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues.

 

CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre.

 


 

Centre for Addiction and Mental Health, 11.01.2012 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…